{
    "clinical_study": {
        "@rank": "121031", 
        "arm_group": {
            "arm_group_label": "Patients with Retinal Vein Occlusion or Diabetic Macular Edema", 
            "description": "Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study."
        }, 
        "brief_summary": {
            "textblock": "This retrospective data review study will evaluate anti-VEGF injections for retinal vein\n      occlusion (RVO) or diabetic macular edema (DME)."
        }, 
        "brief_title": "A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Retinal Vein Occlusion", 
            "Macular Edema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Macular edema in the study eye due to RVO or DME\n\n          -  Received an anti-VEGF injection in the study eye on or after June 2010 for RVO and on\n             or after August 2012 for DME\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Received Anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema\n        (DME)"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918371", 
            "org_study_id": "GMA-OZU-13-598"
        }, 
        "intervention": {
            "arm_group_label": "Patients with Retinal Vein Occlusion or Diabetic Macular Edema", 
            "description": "Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.", 
            "intervention_name": "Anti-VEGF", 
            "intervention_type": "Drug", 
            "other_name": [
                "Avastin\u00ae", 
                "Lucentis\u00ae", 
                "Eylea\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Endothelial Growth Factors", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Patients with Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) \u2264250 \u00b5m on Time Domain (TD) Optical Coherence Tomography (OCT) or \u2264300 \u00b5m on Spectral Domain (SD) OCT in the Study Eye", 
            "safety_issue": "No", 
            "time_frame": "4 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918371"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Patients with BCVA of 20/40 or Better in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients with CTR of \u2264250 \u00b5m on TD OCT or \u2264300 \u00b5m on SD OCT in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients with Both BCVA 20/40 or Better or CTR \u2264250 \u00b5m on TD OCT or \u2264300 \u00b5m on SD OCT in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients with BCVA 20/40 or Worse or CRT \u2265250 \u00b5m on TD OCT or \u2265300 \u00b5m on SD OCT AND, Compared with the Visit 3 Months Before the Current Visit, Patient had a Gain of <1 Line in BCVA or a Decrease of <50 \u00b5m in CRT in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Mean BCVA in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Change from Baseline in BCVA in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4 Years"
            }, 
            {
                "measure": "Percentage of Patients with an Increase from Baseline of \u22652 Lines in BCVA in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4 Years"
            }, 
            {
                "measure": "Percentage of Patients with an Increase from Baseline of \u22653 Lines in BCVA in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4 Years"
            }, 
            {
                "measure": "Change from Baseline in CRT in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4 Years"
            }, 
            {
                "measure": "Time to Improvement of \u22652 Lines in BCVA in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Time to Improvement of \u22653 Lines in BCVA in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Time to Improvement in BCVA to 20/40 or Better in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Time to Improvement in CRT of \u2264250 \u00b5m on TD OCT or \u2264300 \u00b5m on SD OCT in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of \u2264250 \u00b5m on TD OCT or \u2264300 \u00b5m on SD OCT in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Time Between Anti-VEGF Injections in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Number of Anti-VEGF Injections in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Change in BCVA Following the Last Anti-VEGF Injection in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients switching to a 2nd or 3rd Anti-VEGF After the First Injection in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients Switching Among Different Anti-VEGFs in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients with Focal Laser in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients with Panretinal Photocoagulation (PRP) in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients Using Corticosteroids in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients with a Loss, Gain and No Change from Baseline in BCVA by \u22651 Line in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4 Years"
            }, 
            {
                "measure": "Percentage of Patients with Glaucoma Laser Surgery in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Patients with Incisional Glaucoma Surgery in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Percentage of Phakic Patients with Cataract Surgery in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}